Is sirolimus better than paclitaxel? A review of the comparative data on drug-eluting stents

Simon J. Corbett, Rade Babic, John Cosgrave, Giuseppe M. Sangiorgi, Antonio Colombo

Research output: Contribution to journalArticle

Abstract

Drug-eluting stents have been unequivocally demonstrated to reduce in-stent restenosis when compared to bare metal stents, with resultant lower rates of repeat revascularization. Comparative data are now emerging which compare the performance of sirolimus- and paclitaxel-eluting stents to each other rather than to bare metal stents. In this article, we review these data with the aim of placing the studies in context thereby providing an overall view of this rapidly developing field as it stands at present.

Original languageEnglish
Pages (from-to)159-164
Number of pages6
JournalCardiovascular Revascularization Medicine
Volume7
Issue number3
DOIs
Publication statusPublished - Jul 2006

Fingerprint

Drug-Eluting Stents
Sirolimus
Paclitaxel
Stents
Metals

Keywords

  • Paclitaxel
  • Percutaneous coronary intervention
  • Sirolimus
  • Stent

ASJC Scopus subject areas

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Is sirolimus better than paclitaxel? A review of the comparative data on drug-eluting stents. / Corbett, Simon J.; Babic, Rade; Cosgrave, John; Sangiorgi, Giuseppe M.; Colombo, Antonio.

In: Cardiovascular Revascularization Medicine, Vol. 7, No. 3, 07.2006, p. 159-164.

Research output: Contribution to journalArticle

Corbett, Simon J. ; Babic, Rade ; Cosgrave, John ; Sangiorgi, Giuseppe M. ; Colombo, Antonio. / Is sirolimus better than paclitaxel? A review of the comparative data on drug-eluting stents. In: Cardiovascular Revascularization Medicine. 2006 ; Vol. 7, No. 3. pp. 159-164.
@article{3f424538ccb34d7a95399b9d9581b148,
title = "Is sirolimus better than paclitaxel? A review of the comparative data on drug-eluting stents",
abstract = "Drug-eluting stents have been unequivocally demonstrated to reduce in-stent restenosis when compared to bare metal stents, with resultant lower rates of repeat revascularization. Comparative data are now emerging which compare the performance of sirolimus- and paclitaxel-eluting stents to each other rather than to bare metal stents. In this article, we review these data with the aim of placing the studies in context thereby providing an overall view of this rapidly developing field as it stands at present.",
keywords = "Paclitaxel, Percutaneous coronary intervention, Sirolimus, Stent",
author = "Corbett, {Simon J.} and Rade Babic and John Cosgrave and Sangiorgi, {Giuseppe M.} and Antonio Colombo",
year = "2006",
month = "7",
doi = "10.1016/j.carrev.2006.03.106",
language = "English",
volume = "7",
pages = "159--164",
journal = "Cardiovascular Revascularization Medicine",
issn = "1553-8389",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Is sirolimus better than paclitaxel? A review of the comparative data on drug-eluting stents

AU - Corbett, Simon J.

AU - Babic, Rade

AU - Cosgrave, John

AU - Sangiorgi, Giuseppe M.

AU - Colombo, Antonio

PY - 2006/7

Y1 - 2006/7

N2 - Drug-eluting stents have been unequivocally demonstrated to reduce in-stent restenosis when compared to bare metal stents, with resultant lower rates of repeat revascularization. Comparative data are now emerging which compare the performance of sirolimus- and paclitaxel-eluting stents to each other rather than to bare metal stents. In this article, we review these data with the aim of placing the studies in context thereby providing an overall view of this rapidly developing field as it stands at present.

AB - Drug-eluting stents have been unequivocally demonstrated to reduce in-stent restenosis when compared to bare metal stents, with resultant lower rates of repeat revascularization. Comparative data are now emerging which compare the performance of sirolimus- and paclitaxel-eluting stents to each other rather than to bare metal stents. In this article, we review these data with the aim of placing the studies in context thereby providing an overall view of this rapidly developing field as it stands at present.

KW - Paclitaxel

KW - Percutaneous coronary intervention

KW - Sirolimus

KW - Stent

UR - http://www.scopus.com/inward/record.url?scp=33748704814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748704814&partnerID=8YFLogxK

U2 - 10.1016/j.carrev.2006.03.106

DO - 10.1016/j.carrev.2006.03.106

M3 - Article

C2 - 16945823

AN - SCOPUS:33748704814

VL - 7

SP - 159

EP - 164

JO - Cardiovascular Revascularization Medicine

JF - Cardiovascular Revascularization Medicine

SN - 1553-8389

IS - 3

ER -